# Symetis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/symetis

- Industry: Medical Devices & Equipment
- Headquarters: Ecublens, Switzerland
- Website: www.symetis.com
- Total disclosed funding: $9.6M
- Latest round: Series A (Nov 13, 2004)
- Investors on record: 5

## About

Symetis SA is a medical technology firm specializing in the development of innovative heart valve solutions for transcatheter aortic valve implantation (TAVI) procedures. Their products enhance patient care in cardiology.Founded in 2001 in Ecublens, Switzerland, Symetis SA focuses on creating medical devices for heart valve treatments. The company was acquired by Boston Scientific in March 2017 for USD 435 mn, and the deal was completed in May 2017. The acquisition allowed Boston Scientific to expand its portfolio in cardiac care. The company has participated in 5 investment rounds, with the latest being a Secondary Buyout, raising a total of USD 435 mn.Symetis SA offers advanced heart valve devices specifically designed for transcatheter aortic valve implantation (TAVI). Their flagship products include the Acurate neo™ valve, which is engineered for precise placement and optimal hemodynamic performance. These devices are utilized in hospitals worldwide, catering to healthcare professionals and institutions focused on treating patients with severe aortic stenosis.Symetis SA generates revenue through the direct sale of its heart valve devices to healthcare institutions. Its pricing model includes per-unit sales as well as bulk purchasing agreements with hospitals. Additionally, revenue is augmented through partnerships that may offer service agreements and training programs linked to their innovative products.Symetis SA plans to leverage its recent funding round by advancing the development of new heart valve products aimed at enhancing procedural efficiency. Target markets for expansion include North America and key European nations, with planned launches of new products scheduled for late 2024. The funding from Boston Scientific will support these initiatives, aiming to strengthen their market position and improve patient outcomes.

## Funding rounds

- Series A, Nov 13, 2004, $9.6M — Aravis, Truffle Capital, Novartis Venture Fund, BioMed Partners, Gaia Private Equity

## Investors

- Aravis (https://capitalatlas.ai/funds/aravis) — Series A
- Truffle Capital (https://capitalatlas.ai/funds/truffle-capital) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A
- Gaia Private Equity — Series A